JYMed Peptide is pleased to announce that Hubei JXBio Pharmaceutical Co., Ltd, its peptide API manufacturing site, has received Korean Drug Master File (K-DMF) registration for Teriparatide Acetate from South Korea’s Ministry of Food and Drug Safety (MFDS). The...
To All Our Customers, Partners, and Members of the Public: We have recently become aware of fraudulent websites impersonating our company online. These fake websites have been unlawfully copying our corporate information, business descriptions, and other materials and...
Against the backdrop of sustained growth in the global peptide drug industry, and steadily increasing global client demand for GLP-1-class peptides, peptide-drug conjugates (PDCs), peptide CDMO services, and related capabilities, JYMed Peptides (hereinafter referred...
The peptide sector is undergoing a profound transformation. In the early days, the core question from clients was, “Can it be made?” Today, as GLP-1 therapies and other innovative peptide drugs enter large-scale commercialization, pharmaceutical companies are looking...
CPHI China 2026 in Shanghai has officially come to a close, and what an incredible event it was for the global pharmaceutical community. CPHI China 2026 in Shanghai: A Successful Event for JYMed Peptide Over three dynamic days, thousands of pharma professionals,...
May 29 | 1. CSPC enters a $18.5 billion global licensing deal with AstraZeneca for peptide platform (including GLP-1 pipeline) Key Highlights: The deal comprises an upfront payment of $1.2 billion and a total potential value of up to $18.5 billion, setting a new...
中文
